Articles from Care Access

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Margate, Fla. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Newark, N.J. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Jacksonville, Fla. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Houston. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Orlando, Fla. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Memphis, Tenn. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Aurora, Colo. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Chicago. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of College Park, Ga. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Dorchester, Mass. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of New Orleans. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Pearland, Texas. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Mobile, Ala. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Macon, Ga. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access is hosting an Open House event for the community at their Health & Research Center in Thousand Oaks, Calif. Attendees will have the opportunity to tour the facility, meet the team of clinical research professionals, and learn about Care Access’s efforts to improve access to health resources and research opportunities for all communities. The Open House takes place on December 16 from 3:00 PM to 7:00 PM at 2100 Lynn Road, Suite 100, in Thousand Oaks.

Care Access is hosting an Open House event for physicians and healthcare professionals at their Health & Research Center in Thousand Oaks, Calif. Attendees will have the opportunity to tour the facility, meet the team of clinical research professionals, and learn about how they can work together to improve access to health resources and research opportunities for all communities. The Open House takes place on December 16 from 3:00 PM to 7:00 PM at 2100 Lynn Road, Suite 100, in Thousand Oaks.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Lanham, Md. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access is hosting an Open House event for physicians and healthcare professionals at their new Health & Research Center in Decatur, Ga. Attendees will have the opportunity to tour the facility, meet the team of clinical research professionals, and learn about how they can work together to improve access to health resources and research opportunities for all communities. The Open House takes place on December 9 from 3:00 PM to 7:00 PM at 495 Winn Way, Suite 170, in Decatur, Ga.

Care Access is hosting an Open House event for the community at their new Health & Research Center in Decatur, Ga. Attendees will have the opportunity to tour the facility, meet the team of clinical research professionals, and learn about Care Access’s efforts to improve access to health resources and research opportunities for all communities. The Open House takes place on December 9 from 3:00 PM to 7:00 PM at 495 Winn Way, Suite 170, in Decatur, Ga.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Tampa, Fla. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Philadelphia, Pa. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Memphis, Tenn. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Indianapolis, Ind. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access is hosting an Open House event for the community at their new Health & Research Center in Houston. Attendees will have the opportunity to tour the facility, meet the team of clinical research professionals, and learn about Care Access’s efforts to improve access to health resources and research opportunities for all communities. The Open House takes place on December 3 from 3:00 PM to 7:00 PM at 2525 W Bellfort Avenue, Suite 160, in Houston.

Care Access is hosting an Open House event for physicians and healthcare professionals at their new Health & Research Center in Houston. Attendees will have the opportunity to tour the facility, meet the team of clinical research professionals, and learn about how they can work together to improve access to health resources and research opportunities for all communities. The Open House takes place on December 3 from 3:00 PM to 7:00 PM at 2525 W Bellfort Avenue, Suite 160, in Houston.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Palo Alto, Calif. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Detroit, Mich. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Birmingham, Ala. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Irvine. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Indianapolis. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of North Myrtle Beach and nearby communities. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company, Care Access, is making its Heart & Kidney Health Screening initiative available to residents of Hialeah and nearby communities. This health screening raises awareness and provides testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Van Nuys, Calif. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Chicago. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Clarkston, Ga. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Willow Grove, Pa. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Kennesaw, Ga. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Berkeley Heights, N.J. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Slidell, La. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Glendale, Ariz. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Philadelphia, Pa. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Riverside, Calif. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Chicago, Ill. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Houston, Texas. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Health and research company Care Access has partnered with the City of District Heights, Maryland to bring its health screenings to the District Heights Senior Center in the City’s Municipal Building.

Care Access, a global health research company helping to improve access to research that leads to new cures and treatments for diseases, is proud to announce the award of a multimillion-dollar agreement with the Biomedical Advanced Research and Development Authority (BARDA), part of Administration for Strategic Preparedness and Response, within the U.S. Department of Health and Human Services (HHS).

Care Access, a global clinical research site company helping to accelerate the future of medicine, has opened its newest research site in Warsaw, Poland. The company’s expansion in Poland reinforces its commitment to improving access to clinical research globally through its innovative model of bringing clinical trials wherever they are needed.

A cancer research study focusing on hormone receptor-positive HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) is now available to patients in the Clifton, N.J., area.

Adults in the Ogden, Utah area with moderately to severely active ulcerative colitis (UC) may have the opportunity to join a research study assessing a new investigational medication. UC is the most common form of inflammatory bowel disease (IBD), affecting an estimated 5 million people worldwide.

A new diabetes research study is available in Santa Clarita, Calif., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

A new diabetes research study is available in Warwick, R.I., to evaluate a non-drug procedure that may help improve blood sugar without increasing medicines or insulin.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Texas Southern University in Houston, Texas. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is bringing its Heart & Kidney Health Screening initiative to Ventura County. This health screening aims to raise awareness and provide testing for certain health risk factors, including a dangerous type of cholesterol known as lipoprotein(a), or Lp(a), which impacts one in five people and significantly increases the risk of heart disease and stroke.

Care Access, a global clinical research company helping to accelerate the future of medicine, is joining the National Lipid Association (NLA) Industry Council. The collaboration aims to enable more community-based lipidologists to participate in clinical research and create access to cardiometabolic trials for their patients.

A new research study for chronic obstructive pulmonary disease (COPD) exacerbations is now available in Choctaw, Okla. The CRESCENDO study, by AstraZeneca, aims to determine the impact of a once-daily pill on easing symptoms, reducing flare-ups, and improving the quality of life for people with COPD.

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Rock Hill, S.C., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.

A new research study on chronic obstructive pulmonary disease (COPD) is now available in the Greater Houston, Texas, area for a potential treatment for reducing COPD exacerbations. The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD. The study is offered at Care Access locations in Houston, Conroe, Lake Jackson, and Webster.

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Hamilton and Middletown, Ohio, for a potential treatment for reducing COPD exacerbations. The AERIFY-1 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in former smokers with moderate-to-severe COPD.

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Mooresville, N.C., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.

A new research study on chronic obstructive pulmonary disease (COPD) is now available in Wyomissing, Pa., for a potential treatment for reducing COPD exacerbations. The AERIFY-2 study from Sanofi will evaluate if the investigational treatment, itepekimab, reduces dangerous symptom flare-ups in both current and former smokers with moderate-to-severe COPD.

Care Access, a global research company, is enrolling participants at its Warwick, R.I., location to study the effect of an investigational treatment focused on preventing heart attack and stroke in adults with high risk, but no prior history, of major adverse cardiovascular events.

Care Access, a global research company, is enrolling participants at its Santa Clarita, Calif., location to study the effect of an investigational treatment focused on preventing heart attack and stroke in adults with high risk, but no prior history, of major adverse cardiovascular events.

Care Access announced today the completion of a for-cause Food and Drug Administration (“FDA”) Good Clinical Practices (“GCP”) inspection related to Care Access’s activities on the Pfizer VALOR trial. The inspection resulted in no FDA Form 483 observations, meaning the FDA investigator found no GCP violations by Care Access in the VALOR trial. The FDA inspection lasted from October 2nd to October 10th, 2023, and was an in-depth review of Care Access’s contributions to the trial, including with respect to general GCP requirements, patient safety, and data integrity.

A global research study is now available in Tamarac, Fla., for an investigational treatment to help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke. Patients with AFib are known to have a four to five times higher risk of stroke than the general population. Anticoagulant treatments are regularly prescribed by physicians and proven to effectively reduce the incidence of strokes. However, data from multiple registries and claims-based data analyses have shown that anywhere from 40% to 60% of AFib patients are not being optimally treated today. This is especially true in older adults, those with kidney or liver disease, those needing concomitant antiplatelet therapy, and patients with other factors associated with an increased risk of bleeding.

A global research study is now available in Memphis, Tenn., for an investigational medication that may help patients with a history of atrial fibrillation (AFib) decrease their risk of stroke. The LILAC-TIMI 76 study from Anthos Therapeutics, offers a potential new option for Afib patients deemed unsuitable for currently available oral anticoagulants by their physicians.

A cardiovascular research study is now available in Lima for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.

A cardiovascular research study is now available in Dorchester for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.

A cardiovascular research study is now available in Baltimore, Md., for an investigational treatment to help patients with elevated lipoprotein (a), known as Lp(a). Elevated Lp(a) is recognized by healthcare professionals as an important risk factor for cardiovascular disease. However, Lp(a) is often not tested for—and testing is often not covered by insurance—because there are no currently approved treatments for lowering Lp(a). Participants in this study will receive Lp(a) tests at no cost.

Care Access—a global research site enabling clinical research participation for more people—is actively enrolling participants at its Pottsville, Pa., location to study the effect of an investigational treatment for a common form of liver disease that is not related to alcohol consumption.

Care Access - a global research company helping accelerate the arrival of new medicines - is working with seniors at its Lake Charles, La., location on a research study for an investigational treatment which aims to slow or prevent the onset of Alzheimer’s disease symptoms. Alzheimer’s disease impacts one out of nine adults over the age of 65 in the U.S. The TRAILBLAZER-ALZ 3 study, by Eli Lilly and Company, utilizes a new experimental blood test that can detect a biomarker known to identify the early preclinical phase of Alzheimer’s, which can start 10 to 20 years before symptoms appear.

Care Access, a leading global clinical research site, today announced the opening of its first permanent site location in Canada, in Cape Breton, Nova Scotia. Cape Breton is a historically underserved community in clinical trials, and this latest effort in Care Access’ mission to bring clinical research to hard-to-reach and underrepresented communities is the first step in Care Access’ goal to expand clinical trial access across the country. The opening in Canada comes less than a year after Care Access expanded in Brazil with its acquisition of IBPClin in June 2022.

Care Access, the world leader in decentralized clinical trials delivery, today announced the acquisition of Instituto Brasil de Pesquisa Clínica (IBPClin), a clinical trial center in Rio de Janeiro, Brazil, as the first step to bring its decentralized clinical trial delivery model to Latin America, where hard-to-reach, underserved and traditionally underrepresented communities would gain unprecedented access to clinical trials.

Care Access, the world's leader in executing decentralized clinical trials at scale, has announced its upcoming involvement at four key industry conferences: CNS Summit, Outsourcing in Clinical Trials New England (OCTNE), Decentralized Trials & Research Alliance Annual Meeting (DTRA), and Decentralized Trials Digital Week. Care Access leaders will be onsite to discuss the common roadblocks to enrollment in clinical trials today; explore the potential of removing constraints imposed by traditional approaches to running clinical trials; and share examples of how the company’s innovative capabilities have helped sponsors to compress enrollment timelines and increase diversity in clinical trials. Care Access will also provide free COVID-19 rapid antigen testing for all attendees at the DTRA Annual Meeting and the CNS Summit.

Care Access, the world’s leading decentralized research organization (DRO), today announced its expanded partnership with global biopharma leader Eli Lilly and Company (Lilly) to broaden patient access to clinical trials and increase representation of minority group members, including African American, Hispanic, and LatinX populations.